Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 10Colorectal Neoplasms 8Rectal Neoplasms 4Neoplasm Metastasis 3Pancreatic Neoplasms 2Lung Neoplasms 2Immunotherapy 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Mid-low Rectal Cancer 1Locally Advanced Rectal Cancer With Liver Metastases 1Locally Advanced Rectal Cancer 1Liver Metastases of Colorectal Cancer 1Immunotherapy Gastrict Cancer 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Cancer Liver Metastasis 1Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 1Adenocarcinoma 1

Interventions

tislelizumab 2Oxaliplatin 2apatinib 1Tegafur 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Immunotherapy × Oxaliplatin × Clear all
NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Immunotherapy

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting
94 enrolled

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡